Kaydo calls retatrutide the most exciting obesity drug in the pipeline and explains its triple action on GLP-1, GIP and glucagon receptors before adding caveats.
Recap by typeshit. Post by @drkaydo on Instagram.
A Future Health & Medical Innovation panel weighs how much of the growing interest in peptides and exosomes is backed by evidence.
The aging doctor shares a headline saying new studies point to GLP-1 drugs slowing the biological clock, and notes himself that more research is needed.
An explainer on how GLP-1 drugs act on reward and craving in the brain, and the research testing them against alcohol, nicotine and other substance use.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
A short lipidated peptide pulled Nav1.8 pain channels off nerve cell surfaces in a Cell Reports Medicine study. The company says several candidates are now in evaluation.
Polskie Radio covers a newer weight loss drug framed as the next step after Ozempic. Details on which drug are not given here.
Loading…